Sustained Minimal Residual Disease (MRD) Negativity for ≥1 Year in Transplant Eligible Newly Diagnosed Multiple Myeloma (NDMM): A Systematic Review of Prospective Clinical Trials

Key Points

• Sustained minimal residual disease (MRD) negativity for one year supports better prognosis in multiple myeloma patients.
• The systematic review encompasses diverse prospective clinical trials assessing various treatment regimens.
• A focus on transplant-eligible patients highlights the importance of early intervention for optimal outcomes.
• Future studies should explore long-term effectiveness and the applicability of these findings to broader patient populations.